A phase I study of the ceramide nanoliposome in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology · 2024-01 · 93 (1) · 23-29
DOI: 10.1007/s00280-023-04588-7 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 22.09.2023. Verfasst von Aaron Ciner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, U.S. Department of Defense, National Cancer Institute.
Abstract (Originalsprache)
Purpose
Ceramide is a sphingolipid metabolite that deactivates multiple oncogenic signaling pathways and promotes cell death. In-vivo data demonstrate single-agent anti-cancer activity and enhanced efficacy with combination strategies. This phase I dose-escalation trial evaluated Ceramide nanoLiposomes (CNL) in patients with advanced solid tumors and no standard treatment option.
Methods
The primary objective was to establish the maximum tolerated dose. Secondary objectives included determining the recommended phase II dose, the safety and tolerability, the pharmacokinetic profile and preliminary anti-tumor efficacy.
Results
15 patients with heavily pretreated metastatic disease enrolled. Safety data were analyzed for all patients, while pharmacokinetic data were available for 14 patients. There were no grade 3 or higher treatment-related adverse events. The maximum tolerated dose was not reached and there were no dose-limiting toxicities. The most common grade 1 or 2 treatment-related adverse events included headache, fatigue, constipation, nausea and transaminitis. The maximum concentration and area under the curve increased with dose. Clearance was consistent between doses and was observed mainly through the liver without significant hepatotoxicity. The half-life ranged from 20 to 30 h and the volume of distribution was consistent with a lipophilic drug.
Conclusions
CNL exhibited an encouraging safety profile and pharmacokinetic parameters, with some signals of efficacy including prolonged stable disease in 1 patient with refractory pancreatic cancer. Pre-clinical data indicate potential synergy between CNL and multiple systemic therapies including chemotherapy, targeted therapy, and immunotherapy. Future studies are planned investigating CNL in combination strategies.
Trial registration
This study is registered under ClinicalTrials.gov ID: NCT02834611.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
- Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
- Keystone Nano, Boalsburg, PA, USA.
- Department of Pharmacology, University of Virginia, Charlottesville, VA, USA.
- Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA. yjiang@umm.edu.
ORCID-Profile: Yixing Jiang
Förderung
- NCI NIH HHS
- U.S. Department of Defense
- National Cancer Institute
- Cancer Center Support Grant
Zitieren
APA
Ciner, A., Gourdin, T., Davidson, J., Parette, M., Walker, S. J., Fox, T. E., & Jiang, Y. (2024). A phase I study of the ceramide nanoliposome in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 93(1), 23-29. https://doi.org/10.1007/s00280-023-04588-7
Vancouver
Ciner A, Gourdin T, Davidson J, Parette M, Walker SJ, Fox TE, et al. A phase I study of the ceramide nanoliposome in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2024;93(1):23-29. doi:10.1007/s00280-023-04588-7
BibTeX
@article{Ciner2024,
author = {Ciner, Aaron and Gourdin, Theodore and Davidson, Jeff and Parette, Mylisa and Walker, Susan J and Fox, Todd E and Jiang, Yixing},
title = {A phase I study of the ceramide nanoliposome in patients with advanced solid tumors},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
volume = {93},
number = {1},
pages = {23--29},
doi = {10.1007/s00280-023-04588-7}
}
EUVIMED